Heart conduction disorders related to antimalarials toxicity: An analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases

Rheumatology

Volumn 46, Issue 5, 2007, Pages 808-810

  Costedoat Chalumeau, Nathalie ^a   Hulot, J S ^b   Amoura, Z ^a   Leroux, G ^a   Lechat, P ^b   Funck Brentano, C ^c   Piette, J C ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Antimalarials; Atrioventricular block; Electrocardiogram; Heart conduction disorders; Hydroxychloroquine; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; PREDNISONE; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CONNECTIVE TISSUE DISEASE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOLLOW UP; HEART BLOCK; HEART BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION SYSTEM; MIDDLE AGED; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; BUNDLE-BRANCH BLOCK; CONNECTIVE TISSUE DISEASES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART BLOCK; HEART CONDUCTION SYSTEM; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 34347226391     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel402     Document Type: Article

References (17)

1. Estes ML, Ewing-Wilson D, Chou SM et al. Chloroquine nouromyotoxicity. Clinical and pathologic perspective. Am J Med 1987;82:447-55.
2. Costedoat-Chalumeau N, Hulot JS, Amoura Z et al. Cardiomyopathy related to antimalarial therapy with Illustrative case report. Cardiology 2006;107:73-80.
3. Godeau P, Guillevin L, Fechner J, Bletry O, Herreman G. Disorders of conduction in lupus erythematosus: Frequency and incidence in a group of 112 patients. Ann Med Inteme 1981;132:234-40.
4. Piatte JC, Guillevin L, Chapelon C, Wechsler B, Bletry O, Godeau P. Chioroquine cardiotoxicity. N Engl J Med 1987;317:710-1.
5. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol 1999;26:1866-8.
6. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al. Low blood concentration of hydroxycloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
7. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
8. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with OT prolongation and refractory ventricular arrhythmia. Clin Toxicol 2006;44:173-5.
9. Wu J, Kors JA, Rijnbeek PR, van Herpen G, Lu Z, Xu C. Normal limits of the electrocardiogram in Chinese subjects. Int J Cardiol 2003;87:37-51.
10. Dmitrienko AA, Sides GD, Winters KJ et al. Electrocardiogram reference ranges derived from a standardized clinical trial population. Drug Inf J 2005;39: 395-405.
11. Kreger BE, Anderson KM, Kennel WB. Prevalence of intraventricular block in the general population: The Framingham Study. Am Heart J 1989;117:903-10.
12. Fahy GJ, Pinski SL, Miller DP et al. Natural history of isolated bundle branch block. Am J Cardiol 1996;77:1185-90.
13. Keating RJ, Bhatia 8, Amin S, Williams A, Sinak LJ, Edwards WD. Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr 2005;18:981.
14. Fellahi JL, Dumazer P, Delayance S, Vernier I, Conte JJ. Cardiomyopathy under treatment with hydroxychloroquine disclosed by complete auriculoventricular block. Rev Med Intern 1993;14:275-6.
15. August C, Holzhausen HJ, Schmoldt A, Pompecki R, Schroder S. Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med 1995;73:73-7.
16. Baguet JP, Tremal F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart 1999;81:221-3.
17. Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus arythematosus: A report of 2 cases and review of the literature. Semin Arthritis Rheum 2004;33:336-51.